Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2010 09:02 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Conducting Clinical Trial in Patients With Pancreatic Cancer in Dallas

Ongoing Clinical Trial Evaluating a New Approach for Pancreatic Cancer, One of the Most Difficult to Treat Cancers Spotlight on Pancreatic Cancer Awareness Month in November DALLAS, Nov. 15,...
November 10, 2010 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals to Present at Lazard Healthcare Conference

CAMBRIDGE, Mass., Nov. 10, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at the Lazard Capital Markets 7th Annual Healthcare Conference on Wednesday,...
November 09, 2010 16:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Provides Company Update and Reports Third Quarter 2010 Financial Results

CAMBRIDGE, Mass., Nov. 9, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today highlighted its recent business and clinical progress, and announced third quarter 2010 financial...
November 08, 2010 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Augments Executive Leadership Team, Appointing New Chief Medical Officer and New Vice President, Product Development and Medical Affairs

CAMBRIDGE, Mass., Nov. 8, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced two key appointments to its executive leadership team. The company named Pedro...
November 04, 2010 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Awarded Approximately $750,000 in Grants for Qualifying Therapeutic Development Projects

CAMBRIDGE, Mass., Nov. 4, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it has been awarded three grants totaling approximately $750,000 under the U.S....
October 26, 2010 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces That Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Ltd. Exercise Rights to Develop and Commercialize Infinity's FAAH Pain Program Worldwide

Encouraging Topline Data From Phase 1 Study of IPI-940 Reported Decision Demonstrates Strength of Alliance and Underscores Complementary Capabilities of the Partners CAMBRIDGE, Mass., Oct. 26,...
October 25, 2010 08:30 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces the Date of Its Third Quarter 2010 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 25, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will announce its third quarter 2010 financial results on Tuesday, November 9, 2010 after the financial...
October 14, 2010 08:30 ET | Source: Infinity Pharmaceuticals, Inc.

Results Showing Activity of IPI-504 in Patients With Non-Small Cell Lung Cancer Published in Journal of Clinical Oncology

CAMBRIDGE, Mass., Oct. 14, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) announced that results from its Phase 2 study of IPI-504, a novel IV-administered Hsp90 chaperone...
October 10, 2010 06:45 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces Promising Phase 1 Data of IPI-926 in Patients With Advanced or Metastatic Solid Tumors

MILAN, Italy, Oct. 10, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced promising preliminary results from a Phase 1 study of IPI-926, its novel, oral small...
September 22, 2010 08:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals to Present Phase 1 Clinical Data of IPI-926 at ESMO Congress

CAMBRIDGE, Mass., Sept. 22, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right